The Filing Desk

Enanta Pharmaceuticals vs Tango Therapeutics

Enanta Pharmaceuticals ENTA · Tango Therapeutics TNGX · Pharmaceuticals

Enanta Pharmaceuticals reported revenue of $63 million in fiscal 2026, about the same as Tango Therapeutics' $62 million in fiscal 2025. Enanta Pharmaceuticals' revenue fell 3.6% in its latest year, and Tango Therapeutics' grew 48.3%. Enanta Pharmaceuticals had an operating margin of -99.0%, against -178.4% at Tango Therapeutics. Free cash flow was −$43 million at Enanta Pharmaceuticals and −$140 million at Tango Therapeutics. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.

Side by side

Enanta PharmaceuticalsTango Therapeutics
Latest fiscal yearFY2026, Sep 30, 2026FY2025, Dec 31, 2025
Revenue$63M$62M
Revenue growth−3.6%48.3%
Revenue growth a year, last 5 years−8.3%52.0%
Gross margin——
Operating margin−99.0%−178.4%
Net margin−108.3%−162.8%
Free cash flow−$43M−$140M
Free cash flow margin−67.9%−224.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count35.9%6.3%
Last close$7.98$22.71
P/E at the last close——
Insider trades, last 12 monthssold $183,168sold $7.2 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Enanta PharmaceuticalsTango Therapeutics
Operating margin
Percent of revenue
Enanta PharmaceuticalsTango Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Enanta PharmaceuticalsTango Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Enanta Pharmaceuticals and Tango Therapeutics pages.